racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 53 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



cont
Q 1

Claim 54 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 55 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable

salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 56 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 57 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 58 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 59 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



cn't
Q 1

Claim 60 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 61 (New Claim): A pharmaceutical composition comprising as an active ingredient a compound, including enantiomers, stereoisomers,

rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being selected from the following:







cont
Q 1















Claim 62 (New Claim): The pharmaceutical composition of claim 61, additionally containing an antiviral agent.

Claim 63 (New Claim): The pharmaceutical composition of claim 62, still additionally containing an interferon or PEG-interferon alpha conjugate.

Claim 64 (New Claim): The pharmaceutical composition of claim 63, wherein said antiviral agent is ribavirin and said interferon is α-interferon.

Claim 65 (New Claim): A method of treating disorders associated with the HCV, said method comprising administering to a patient in need of such treatment, a pharmaceutical composition which comprises therapeutically effective amounts of a compound, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being selected from the following:

cont
a1







cont
Q_1